KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Other Operating Expenses: 2020-2024

Historic Other Operating Expenses for Castle Biosciences (CSTL) over the last 5 years, with Dec 2024 value amounting to $71.3 million.

  • Castle Biosciences' Other Operating Expenses rose 17.33% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 61.57%. This contributed to the annual value of $71.3 million for FY2024, which is 32.07% up from last year.
  • Castle Biosciences' Other Operating Expenses amounted to $71.3 million in FY2024, which was up 32.07% from $54.0 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Other Operating Expenses peaked at $71.3 million during FY2024, and registered a low of $1.9 million during FY2020.
  • Its 3-year average for Other Operating Expenses is $49.1 million, with a median of $54.0 million in 2023.
  • Data for Castle Biosciences' Other Operating Expenses shows a peak YoY surged of 844.74% (in 2021) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Other Operating Expenses (Yearly) stood at $1.9 million in 2020, then skyrocketed by 844.74% to $17.8 million in 2021, then increased by 23.67% to $22.0 million in 2022, then surged by 145.57% to $54.0 million in 2023, then spiked by 32.07% to $71.3 million in 2024.